Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.
Imara, the US-based hemoglobinopathy drug developer backed by pharmaceutical firms Lundbeck and Pfizer, went public yesterday in a $75.2m initial public offering on the Nasdaq Global Select Market.
The offering consisted of 4.7 million shares priced at $16.00 each, increasing the number slightly from 4.45 million. The company floated at the low end of the IPO’s $16 to $18 range and the IPO valued it at approximately $265m.
Founded in 2016, Imara is developing therapeutics for inherited genetic disorders…
